6505--Intent to Sole Source PYLARIFY (piflufolastat F 18)
| Agency: | VETERANS AFFAIRS, DEPARTMENT OF |
|---|---|
| State: | Federal |
| Type of Government: | Federal |
| FSC Category: |
|
| NAICS Category: |
|
| Posted Date: | Aug 19, 2025 |
| Due Date: | Aug 26, 2025 |
| Solicitation No: | 36C25225Q0655 |
| Original Source: | Please Login to View Page |
| Contact information: | Please Login to View Page |
| Bid Documents: | Please Login to View Page |
Description
Follow
Active
Contract Opportunity
Notice ID
36C25225Q0655
Related Notice
Department/Ind. Agency
VETERANS AFFAIRS, DEPARTMENT OF
Sub-tier
VETERANS AFFAIRS, DEPARTMENT OF
Office
252-NETWORK CONTRACT OFFICE 12 (36C252)
General Information
Classification
Description
Contact Information
History
- Contract Opportunity Type: Special Notice (Original)
- Original Published Date: Aug 19, 2025 11:40 am EDT
- Original Response Date: Aug 26, 2025 05:00 pm EDT
- Inactive Policy: Manual
- Original Inactive Date: Aug 31, 2025
-
Initiative:
- None
- Original Set Aside:
- Product Service Code: 6505 - DRUGS AND BIOLOGICALS
-
NAICS Code:
- 325412 - Pharmaceutical Preparation Manufacturing
-
Place of Performance:
The Department of Veterans Affairs, VHA Regional Procurement Office Central, Great Lakes Acquisition Center, Network Contracting Office 12, located at 115 S. 84th Street, Suite 101, Milwaukee, WI 53214-1476 intends to award a sole source, firm-fixed-price delivery order to Progenics Pharmaceuticals, Inc. 331 Treble Cove Road, N. Billerica, MA 01862, for the purchase of Pylarify Injection (Piflufolastat F 18). The associated North America Classification Systems (NAICS) Code is 325412, Pharmaceutical Preparation Manufacturing.
The Edward J. Hines, Jr. VA Medical Center, 5000 South 5th Avenue, Hines, IL, 60141-3030, has a requirement for the purchase of Pylarify Injection (Piflufolastat F 18). Pylarify (piflufolastate F18) is highly specialized radiopharmaceutical. Pylarify is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Pylarify combines the accuracy of PET imaging, the precision of PSMA targeting, and the clarity of F18 radioisotope. Per the FDA website https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Pylarify is manufactured for and a trademark of Progenics Pharmaceuticals, Inc.
This notice satisfies the requirement at FAR 5.201(b)(1), to publicize the proposed contract action. This notice of intent is not a request for competitive proposals. No solicitation documents are available at this time. Interested parties may give written notice to Stacy.Massey@va.gov by 5:00pm e.s.t. on 08/26/2025. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to meet the subject requirement. This information shall be provided at no cost or obligation to the Government. Responses will be considered by the Government; however, a determination by the Government not to compete the proposed acquisition based upon responses of this notice is solely within the discretion of the Government.
Inquiries shall be emailed to Stacy.Massey@va.gov. No telephone requests will be accepted. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government in future procurements.
The Edward J. Hines, Jr. VA Medical Center, 5000 South 5th Avenue, Hines, IL, 60141-3030, has a requirement for the purchase of Pylarify Injection (Piflufolastat F 18). Pylarify (piflufolastate F18) is highly specialized radiopharmaceutical. Pylarify is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy and or with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. Pylarify combines the accuracy of PET imaging, the precision of PSMA targeting, and the clarity of F18 radioisotope. Per the FDA website https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Pylarify is manufactured for and a trademark of Progenics Pharmaceuticals, Inc.
This notice satisfies the requirement at FAR 5.201(b)(1), to publicize the proposed contract action. This notice of intent is not a request for competitive proposals. No solicitation documents are available at this time. Interested parties may give written notice to Stacy.Massey@va.gov by 5:00pm e.s.t. on 08/26/2025. Supporting evidence must be furnished in sufficient detail to demonstrate the ability to meet the subject requirement. This information shall be provided at no cost or obligation to the Government. Responses will be considered by the Government; however, a determination by the Government not to compete the proposed acquisition based upon responses of this notice is solely within the discretion of the Government.
Inquiries shall be emailed to Stacy.Massey@va.gov. No telephone requests will be accepted. Any response to this notice must show clear and convincing evidence that competition would be advantageous to the Government in future procurements.
Attachments/Links
Contracting Office Address
- GREAT LAKES ACQUISITION CENTER 115 S 84TH ST
- MILWAUKEE , WI 53214
- USA
Primary Point of Contact
- Stacy Massey
- Stacy.Massey@va.gov
- Phone Number 4148448400
Secondary Point of Contact
- Aug 19, 2025 11:40 am EDTSpecial Notice (Original)
Get Government Bids Like This by Email
Receive daily bid alerts that match your keywords, business categories, and target regions.
See Also
Follow Dapagliflozin Tablets Active Contract Opportunity Notice ID SPE2D2-26-R-0018 Related Notice Department/Ind. Agency
DEPT OF DEFENSE
Follow Progesterone Capsules Active Contract Opportunity Notice ID SPE2D2-26-R-0015 Related Notice SPE2D2-26-R-0015 Department/Ind.
DEPT OF DEFENSE
Due by 9/18/2026
Follow 65--SURVIVAL KIT,INDIVIDUA Active Contract Opportunity Notice ID SPE2DS26T414R Related Notice Department/Ind. Agency
DEPT OF DEFENSE
Due by 9/15/2026
Follow 6505--Ticagrelor Tablets Active Contract Opportunity Notice ID 36E79726R0028 Related Notice 36E79726R0028 Department/Ind.
VETERANS AFFAIRS, DEPARTMENT OF
Due by 9/17/2026
* Disclaimer: This website provides information about bids, requests for proposals (RFPs), or requests for qualifications (RFQs) for convenience only and does not serve as an official public notice. Individuals who wish to respond to or inquire about bids, RFPs, or RFQs should contact the relevant government department directly.